
Opinion|Videos|April 9, 2025
Advances in the Understanding of Hypercortisolism
Experts discuss the long-term health impacts of hypercortisolism, including unresolved comorbidities and increased mortality risk, the consequences of delayed diagnosis, and how the understanding of its clinical presentation has evolved.
Advertisement
Episodes in this series

Video content above is prompted by the following:How can hypercortisolism affect a patient’s long-term health and quality of life?
- Long-term risks remain for patients even if hypercortisolism remission is achieved, including incomplete resolution of comorbidities, reduced quality of life, and increased mortality risk.
- What are some of the consequences of a delayed or missed hypercortisolism diagnosis?
- Increased risk of cardiometabolic abnormalities, osteoporosis, and psychiatric disorders
- Increase in mortality rate compared with the general population
- How has our understanding of the clinical presentation of hypercortisolism evolved?
- Overt, hallmark symptoms and features vs nonspecific features and symptoms overlapping with chronic disease
Advertisement
Related to this article

Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.

Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.

Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.

Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.

Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.

Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.

Hepatology in September 2026: brelovitug meets phase 3 AZURE-1 endpoint in hepatitis D, plus new US alcohol use data and ALD insights.
Advertisement
Advertisement
Trending on HCPLive
1
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
2
From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class
3
Advances in Treating High-Impact Psoriasis from EADV 2026
4
FDA Updates Sotatercept Label, ERS Releases PAH Guidelines Based on HYPERION Data
5

